Software-as-a-Service Company for clinical trials, Medidata has launched a new company, named Acorn AI, which is aimed at offering actionable insights across the entire drug gamut, from R&D to commercialization. According to the reports, Powered by 2 decades of investments amounting more than USD1 billion in platforms, data pipelines, data science and automation, Acorn AI is the next horizon of the company’s 20-year journey of powering smarter treatments and healthier people. Medidata’s new company is designed to solve companies’ intricate scientific and commercial challenges, comprising a portfolio of new products which allows superior decisions, enhance study success and pace, and assist in exhibiting value to regulators, payers, providers, and the patient.
Besides, Acorn AI is intended to offer actionable insights to the front lines of decision-making by making data liquid across the entire lifecycle, from R&D to commercialization. By utilizing the company’s Artificial Intelligence capabilities and expertise, clients and partners can now let loose the power of data to overcome the most intricate diseases. It’s developed on top of the Medidata platform, involved over 17,000 clinical trials and the industry’s largest structured, standardized clinical data repository with more than 4.8 million patients. Moreover, Acorn AI immediately becomes one of the leading AI companies devoted to life sciences.
For solving companies’ most multifaceted scientific and commercial challenges, Acorn AI is proposing new products, including a Value Discovery Engine to make better go/no-go decisions; Integrated Evidence to help demonstrate value to regulators, payors, providers and patients; Intelligent Trials to improve study success and speed; and Connected Devices to integrate the new generation of medical devices within the digital healthcare ecosystem.